STAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks

A Food and Drug Administration advisory panel on Wednesday endorsed Galleri, a blood test designed by the biotech firm Grail to screen for multiple types of cancer, concluding that the benefits of the test outweighed its risks. The panel voted 10 to 0 that it believed there is “reasonable assurance” the test is safe.The panel voted 6 to 4 that there was reasonable assurance the test is effective. And it voted 7 to 2 with one abstention that it believed “the benefits of Galleri outweigh the risk ...